Health and economic burden of metabolic comorbidity among individuals with bipolar disorder.

J Clin Psychopharmacol

Schizophrenia/Bipolar Disorder and Psychopharmacology Programs, McLean Division of Massachusetts General Hospital, Belmont, MA 02478, USA.

Published: December 2009

Objectives: To compare the prevalence and health care costs of metabolic conditions in patients with bipolar disorder to age- and sex-matched control patients using a large insurance claims database.

Methods: A retrospective analysis of medical service and prescription claims from the Thomson Reuters (Healthcare) MarketScan Commercial Database (which includes claims information on >12 million employees with employer-based insurance and their dependents in the United States) was conducted. Claims data for 28,531 patients with bipolar disorder were compared for 1 year with data for 85,593 age- and sex-matched control patients with no mental health disorders and no psychotropic medication use.

Results: Patients with bipolar disorder had a significantly higher prevalence of metabolic comorbidities than the general population (37% vs 30%, P < 0.0001), and annual medical service treatment costs for metabolic conditions were twice that of the control cohort (531 dollars vs 233 dollars, P < 0.0001). The bipolar cohort had significantly higher overall medical service and prescription drug costs than those of the control cohort (12,764 dollars vs 3,140 dollars, P < 0.0001). Prescription medication costs for metabolic conditions were higher as well, with bipolar cohort per-patient costs of 571 dollars versus 301 dollars for the control cohort (P < 0.0001).

Conclusions: Patients with bipolar disorder have significantly more metabolic comorbidities and higher medical costs than age- and sex-matched controls. Studies that link claims data with medical records or primary data collection pertaining to metabolic conditions may overcome limitations in the diagnostic information and outcome predictors. To reduce the medical and economic burden of bipolar disorder, strategies should be identified to prevent the development of metabolic comorbidities and improve medication adherence.

Download full-text PDF

Source
http://dx.doi.org/10.1097/JCP.0b013e3181bef8a6DOI Listing

Publication Analysis

Top Keywords

bipolar disorder
24
metabolic conditions
16
patients bipolar
16
costs metabolic
12
age- sex-matched
12
medical service
12
metabolic comorbidities
12
control cohort
12
economic burden
8
metabolic
8

Similar Publications

Psychotic disorders, such as schizophrenia and bipolar disorder, pose significant diagnostic challenges with major implications on mental health. The measures of resting-state fMRI spatiotemporal complexity offer a powerful tool for identifying irregularities in brain activity. To capture global brain connectivity, we employed information-theoretic metrics, overcoming the limitations of pairwise correlation analysis approaches.

View Article and Find Full Text PDF

Bipolar disorder (BD) is characterized by temporal instability of mood and energy, but the neural correlates of this instability are poorly understood. In previous cross-sectional studies, mood state in BD has been associated with differential functional connectivity (FC) amongst several subcortical regions and ventromedial prefrontal cortex. Here, we assess whether BD is associated with longitudinal instability within this mood-related network of interest (NOI).

View Article and Find Full Text PDF

Prevalence and predictors of obstructive sleep apnea in patients with bipolar disorder: A systematic review and meta-analysis.

Pak J Med Sci

January 2025

Kailong Gu Department of Geriatric Psychiatry, Huzhou Third Municipal Hospital, The Affiliated Hospital of Huzhou University, Huzhou, Zhejiang Province 313000, China.

Background & Objective: Obstructive sleep apnea (OSA) has been increasingly recognized as a comorbidity in many psychiatric disorders, including bipolar disorder (BD). This study aimed to synthesize existing evidence to determine the frequency of OSA in patients diagnosed with BD and identify potential predictors of its occurrence.

Methods: PubMed, Scopus, CENTRAL (Cochrane Central Register of Controlled Trials), and Google Scholar databases were searched for English-language papers published up from 1 January 1960 to 31 October 2023 that reported incidences of OSA in patients with BP and provided sufficient data for quantitative analysis.

View Article and Find Full Text PDF

Purpose Of The Review: Accidental autoerotic death, more commonly known as "autoerotic asphyxia," is an extreme paraphilic behavior wherein individuals induce cerebral hypoxia during self-stimulated sexual activities, often by constricting the neck or obstructing respiratory passages. Data on accidental deaths caused by autoerotic play is very low because of the non-disclosure of the mode/circumstances of death or non-paralleled forensic systems in many countries. There is a high likelihood of coexisting mental disorders with such behavior.

View Article and Find Full Text PDF

Chronobiologic treatments for mood disorders.

Handb Clin Neurol

January 2025

Division of Neuroscience, IRCCS Ospedale San Raffaele, Milano, Italy.

Chronotherapeutics are nonpharmacologic interventions whose development stems from investigations into sleep and circadian rhythm abnormalities associated with mood disorder. These therapies utilize controlled exposure to environmental cues (light, darkness) to regulate biologic rhythms. They encompass sleep-wake manipulations (partial/total sleep deprivation, sleep phase adjustment) and light therapy approaches.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!